Get the Stockscreener App
6.24
1.46%
+0.09
Mesoblast Ltd ADR stock is currently priced at $6.24, with a 24-hour trading volume of 323.83K.
It has seen a +1.46% increased in the last 24 hours and a +58.78% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.11 pivot point. If it approaches the $6.32 resistance level, significant changes may occur.
Previous Close:
$6.15
Open:
$6.04
24h Volume:
323.83K
Market Cap:
$711.80M
Revenue:
$7.50M
Net Income/Loss:
$-81.89M
P/E Ratio:
0.2232
EPS:
27.9585
Net Cash Flow:
$-63.58M
1W Performance:
+19.77%
1M Performance:
+58.78%
6M Performance:
+433.33%
1Y Performance:
+104.59%
1D Range:
$6.04
$6.36
52W Range:
$0.9703
$7.36
Mesoblast Ltd ADR Stock (MESO) Company Profile
Name
Mesoblast Ltd ADR
Sector
Industry
Phone
61 3 9639 6036
Address
55 Collins Street, Level 38, Melbourne, VIC
Mesoblast Ltd ADR Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd ADR Stock (MESO) Latest News
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
Benzinga
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Model N, Ducommun, Perpetua Resources And Other Big Stocks Moving Higher On Monday
Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
Mesoblast Ltd ADR Stock (MESO) Financials Data
Mesoblast Ltd ADR (MESO) Revenue 2024
MESO reported a revenue (TTM) of $7.50 million for the quarter ending June 30, 2023, a -26.54% decline year-over-year.
Mesoblast Ltd ADR (MESO) Net Income 2024
MESO net income (TTM) was -$81.89 million for the quarter ending June 30, 2023, a +10.35% increase year-over-year.
Mesoblast Ltd ADR (MESO) Cash Flow 2024
MESO recorded a free cash flow (TTM) of -$63.58 million for the quarter ending June 30, 2023, a +3.68% increase year-over-year.
Mesoblast Ltd ADR (MESO) Earnings per Share 2024
MESO earnings per share (TTM) was $53.02 for the quarter ending June 30, 2023, a -23.24% decline year-over-year.
About Mesoblast Ltd ADR
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
1.53%
3.38%
Cap:
|
Volume (24h):